Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response

…, K Yamakado, A Nakatsuka, O Hataji… - Journal of vascular and …, 2004 - Elsevier
PURPOSE: To evaluate the feasibility, safety, and initial therapeutic effect of radiofrequency
(RF) ablation in the treatment of unresectable malignant lung tumors. MATERIALS AND …

Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse

…, S Tamaki, T Kobayashi, O Hataji… - American Journal of …, 2001 - atsjournals.org
It is well recognized that activation of the coagulation system plays an important role in
bleomycin (BLM)-induced lung injury and fibrosis. The protein C (PC) pathway is an important …

[HTML][HTML] Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with …

…, K Yoshimori, Y Takiguchi, O Hataji… - Supportive Care in …, 2016 - Springer
Purpose Although cancer cachexia is mainly characterized by persistent loss of body weight
(BW), usually in response to a malignancy, the pathophysiology of cachexia remains …

Home high-flow nasal cannula oxygen therapy for stable hypercapnic COPD: a randomized clinical trial

…, T Tsuboi, M Yoshida, O Hataji… - American Journal of …, 2022 - atsjournals.org
Rationale: The long-term effects of using a high-flow nasal cannula for chronic hypercapnic
respiratory failure caused by chronic obstructive pulmonary disease remain unclear. …

[HTML][HTML] A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis

…, T Yasuma, M Toda, H Kim, H Fujimoto, O Hataji… - Nature …, 2020 - nature.com
Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown etiology;
however, apoptosis of lung alveolar epithelial cells plays a role in disease progression. This …

[HTML][HTML] Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

…, J Shimizu, H Saito, H Sakai, YH Kim, O Hataji… - Lung Cancer, 2020 - Elsevier
Objectives To describe the treatment patterns and determine the effectiveness and safety of
nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan. …

[HTML][HTML] Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis

…, M Toda, AM Abdel-Hamid, H Fujimoto, O Hataji… - Nature …, 2022 - nature.com
Idiopathic pulmonary fibrosis is an incurable disease of unknown etiology. Acute exacerbation
of idiopathic pulmonary fibrosis is associated with high mortality. Excessive apoptosis of …

Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice

H Yuda, Y Adachi, O Taguchi, EC Gabazza, O Hataji… - Blood, 2004 - ashpublications.org
Asthma is one of the most common diseases and is characterized by airway obstruction, airway
inflammation, and increased airway responsiveness. Glucocorticoids are very effective in …

[HTML][HTML] Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer …

…, S Teraoka, K Usui, K Nishino, O Hataji… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Studies have suggested that chemotherapy after immune checkpoint inhibitors
may confer an improved response for non–small cell lung cancer (NSCLC). However, …

[HTML][HTML] Sequential therapy with crizotinib and alectinib in ALK-rearranged non–small cell lung cancer—a multicenter retrospective study

K Ito, O Hataji, H Kobayashi, A Fujiwara… - Journal of Thoracic …, 2017 - Elsevier
Introduction Alectinib and crizotinib have been approved for the therapy of NSCLC caused
by anaplastic lymphoma kinase gene (ALK) rearrangement. The effect of alectinib or …